GSK laid out $5.1B last year for Tesaro and its cancer med Zejula, and with some new ovarian cancer data, it has another chance to prove the deal was worth it…
Publicis Health Media aims to create a media marketplace for pharma and healthcare with an event styled on the traditional Upfront confabs for TV.
J&J has been defending itself against thousands of lawsuits claiming harm from talc, but it also as a criminal probe to contend with, Bloomberg reports.
Germany’s health technology assessment agency found that the majority of new drugs provide little or no added benefit over standard care.
Peanut-allergy drugmakers Aimmune Therapeutics and DBV Technologies said ICER was premature in calling their medicines unaffordable.
Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.
They say a picture’s worth a thousand words, and Sanofi and Regeneron are using that exchange rate to their advantage with Libtayo.
As a high-profile PCSK9 patent battle plays out in the U.S., Amgen won an injunction in Germany blocking Praluent, Sanofi and Regeneron's rival med.
Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs using drones. Now, Merck & Co. is testing the method.
Sales of Lilly’s Emgality have lagged behind rivals. And to bring payers on board, Lilly is deploying a full-court press with new patient data.